Brain metastases are tumors that occur when cancer cells spread to the brain from another part of the body. They are more common than primary brain tumors and can cause headaches, seizures, neurologic deficits, and changes in cognition.
The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
Phase III data showed dirozalkib improved progression-free survival and intracranial efficacy versus crizotinib in first-line ALK-positive advanced NSCLC. The drug received NMPA approval in August 2025.
The antibody-drug conjugate sacituzumab tirumotecan demonstrated significant survival benefits in pretreated EGFR-mutated NSCLC, with median overall survival of 20.0 months versus 13.5 months for docetaxel. The treatment also showed superior progression-free survival and objective response rates with a favorable safety profile compared to chemotherapy.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Recent studies demonstrate high response rates for antibody-drug conjugate in rare blood cancer, improved outcomes with metastasis-directed radiation in prostate cancer, and a novel drug combination strategy for ovarian cancer resistance.
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
New research warns AI pathology systems may use statistical shortcuts rather than biological signals, while a clinical trial shows stereotactic radiation improves quality of life for patients with multiple brain metastases compared to whole brain radiation.
Phase III trial of 196 patients shows stereotactic radiation targeting individual tumors significantly improved symptom burden and daily functioning compared with hippocampal-avoidance whole-brain radiation, without compromising survival.
Precision oncology has transformed brain metastases treatment from lung cancer, extending survival from 6-12 months to 3-5 years through targeted therapies, immunotherapy, and radiosurgery. With 100,000-200,000 annual cases in the US, multidisciplinary approaches now manage this once-terminal condition as a chronic disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07569263 |
IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases |
NOT_YET_RECRUITING | PHASE1 |
| NCT07539753 |
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases |
NOT_YET_RECRUITING | PHASE2 |
| NCT07481786 |
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases |
RECRUITING | PHASE3 |
| NCT07464470 |
Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers |
RECRUITING | |
| NCT07462507 |
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1 |
RECRUITING | PHASE2 |
| NCT07454668 |
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases |
NOT_YET_RECRUITING | PHASE1 |
| NCT07448493 |
Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer |
ACTIVE_NOT_RECRUITING | |
| NCT07373951 |
Retrospective Multicenter Study of Patient-level T1CE/FLAIR MRI Deep Learning to Predict EGFR/ALK Driver Status in NSCLC Brain Metastases With External Validation and Survival Analysis |
ENROLLING_BY_INVITATION | |
| NCT07365410 |
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07355348 |
Feasibility of a Cognitive Stepped Care Program for Adults With Brain Metastases |
RECRUITING | NA |
